{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:32:45Z","timestamp":1784842365541,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960754"],"award-info":[{"award-number":["81960754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011191","name":"Kunming Institute of Zoology, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.intimp.2021.108383","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:05:22Z","timestamp":1637197522000},"page":"108383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV"],"prefix":"10.1016","volume":"102","author":[{"given":"Zhengchao","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixiong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"NaYin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runfang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-1428","authenticated-orcid":false,"given":"Chunping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.intimp.2021.108383_b0005","first-page":"1824","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): a Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"10249","key":"10.1016\/j.intimp.2021.108383_b0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2021.108383_b0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2021.108383_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.06.043","article-title":"Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data","volume":"27","author":"Paris","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"15","key":"10.1016\/j.intimp.2021.108383_b0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide Mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.intimp.2021.108383_b0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"10240","key":"10.1016\/j.intimp.2021.108383_b0035","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.intimp.2021.108383_b0040","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1097\/QAD.0b013e32833c6d5c","article-title":"Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals","volume":"24","author":"Tebas","year":"2010","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.intimp.2021.108383_b0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.108383_b0050","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell responses to SARS-CoV-2 coronavirus in Humans with COVID-19 disease And unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.intimp.2021.108383_b0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1159\/000509368","article-title":"Strategies to prevent SARS-CoV-2-mediated eosinophilic disease in association with COVID-19 vaccination and Infection","volume":"181","author":"Simon","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2021.108383_b0060","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1084\/jem.155.3.734","article-title":"T cell-derived B cell differentiation factor(s)effect on the isotype switch of murine B cells","volume":"155","author":"Isakson","year":"1982","journal-title":"J Exp Med"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921010195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921010195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:35:03Z","timestamp":1761586503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921010195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":12,"alternative-id":["S1567576921010195"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108383","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108383"}}